Literature DB >> 8801329

The cobalt(III)-insulin hexamer is a prolonged-acting insulin prodrug.

P Kurtzhals1, B Kiehr, A R Sørensen.   

Abstract

The insulin hexamer has two high-affinity metal ion binding sites, each involving three HisB10 residues, one from each dimer. Insulin hexamers containing Co2+ at both these sites were oxidized to form a stable Co(3+)-insulin complex. It is shown that the Co(3+)-coordinated insulin monomers are released extremely slowly in aqueous solution at pH 8.0, and that the hexamer does not spontaneously dissociate into subunits at nanomolar concentrations of insulin. The Co(3+)-insulin hexamer is not recognized by the insulin receptor in vitro but the complex shows a protracted action profile following subcutaneous (s.c.) injection into rabbits. The Co(3+)-insulin hexamer provides a novel prodrug approach to a soluble, prolonged-acting insulin preparation of potential use for basal insulin delivery in the treatment of diabetes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8801329     DOI: 10.1002/jps.2600841006

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  3 in total

1.  Insulin Hexamer-Caged Gadolinium Ion as MRI Contrast-o-phore.

Authors:  Steven K Taylor; Timothy H Tran; Michael Z Liu; Paul E Harris; Yanping Sun; Sachin R Jambawalikar; Liang Tong; Milan N Stojanovic
Journal:  Chemistry       Date:  2018-07-04       Impact factor: 5.236

2.  Glucose-responsive insulin by molecular and physical design.

Authors:  Naveed A Bakh; Abel B Cortinas; Michael A Weiss; Robert S Langer; Daniel G Anderson; Zhen Gu; Sanjoy Dutta; Michael S Strano
Journal:  Nat Chem       Date:  2017-09-22       Impact factor: 24.427

3.  Photoacoustic imaging reveals mechanisms of rapid-acting insulin formulations dynamics at the injection site.

Authors:  Anjul Khadria; Chad D Paavola; Konstantin Maslov; Francisco A Valenzuela; Andrea E Sperry; Amy L Cox; Rui Cao; Junhui Shi; Patricia L Brown-Augsburger; Emmanuel Lozano; Ross L Blankenship; Ranajoy Majumdar; Scott A Bradley; John M Beals; Sunday S Oladipupo; Lihong V Wang
Journal:  Mol Metab       Date:  2022-06-04       Impact factor: 8.568

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.